Specific roles of each TCR hemichain in generating functional chain-centric TCR

Journal of Immunology

Volumn 194, Issue 7, 2015, Pages 3487-3500

  Nakatsugawa, Munehide ^a   Yamashita, Yuki ^a   Ochi, Toshiki ^a   Tanaka, Shinya ^a,b   Chamoto, Kenji ^a   Guo, Tingxi ^a,c   Butler, Marcus O ^a,c   Hirano, Naoto ^a,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b TAKARA BIO INC   (Japan)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MELAN A; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; T LYMPHOCYTE RECEPTOR HEMICHAIN; UNCLASSIFIED DRUG; COMPLEMENTARITY DETERMINING REGION; EPITOPE; HLA A2 ANTIGEN; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE FRAGMENT; PROTEIN BINDING;

ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CELL ISOLATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; T LYMPHOCYTE RECEPTOR ALPHA CHAIN GENE; T LYMPHOCYTE RECEPTOR BETA CHAIN GENE; T LYMPHOCYTE SUBPOPULATION; AMINO ACID SEQUENCE; CELL LINE; CHEMISTRY; COMPLEMENTARITY DETERMINING REGION; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; PROTEIN MULTIMERIZATION; TUMOR CELL LINE;

AMINO ACID SEQUENCE; CELL LINE; CELL LINE, TUMOR; COMPLEMENTARITY DETERMINING REGIONS; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; IMMUNOPHENOTYPING; MART-1 ANTIGEN; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTE SUBSETS; TRANSDUCTION, GENETIC;

EID: 84925871331     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401717     Document Type: Article

References (85)

1. Turner, S. J., P. C. Doherty, J. McCluskey, and J. Rossjohn. 2006. Structural determinants of T-cell receptor bias in immunity. Nat. Rev. Immunol. 6: 883-894.
2. Venturi, V., D. A. Price, D. C. Douek, and M. P. Davenport. 2008. The molecular basis for public T-cell responses? Nat. Rev. Immunol. 8: 231-238.
3. Miles, J. J., D. C. Douek, and D. A. Price. 2011. Bias in the αβ T-cell repertoire: implications for disease pathogenesis and vaccination. Immunol. Cell Biol. 89: 375-387.
4. Dong, L., P. Li, T. Oenema, C. L. McClurkan, and D. M. Koelle. 2010. Public TCR use by herpes simplex virus-2-specific human CD8 CTLs. J. Immunol. 184: 3063-3071.
5. Brennan, R. M., J. Petersen, M. A. Neller, J. J. Miles, J. M. Burrows, C. Smith, J. McCluskey, R. Khanna, J. Rossjohn, and S. R. Burrows. 2012. The impact of a large and frequent deletion in the human TCR β locus on antiviral immunity. J. Immunol. 188: 2742-2748.
6. Archbold, J. K., W. A. Macdonald, S. Gras, L. K. Ely, J. J. Miles, M. J. Bell, R. M. Brennan, T. Beddoe, M. C. Wilce, C. S. Clements, et al. 2009. Natural micropolymorphism in human leukocyte antigens provides a basis for genetic control of antigen recognition. J. Exp. Med. 206: 209-219.
7. Godfrey, D. I., J. Rossjohn, and J. McCluskey. 2008. The fidelity, occasional promiscuity, and versatility of T cell receptor recognition. Immunity 28: 304-314.
8. Yokosuka, T., K. Takase, M. Suzuki, Y. Nakagawa, S. Taki, H. Takahashi, T. Fujisawa, H. Arase, and T. Saito. 2002. Predominant role of T cell receptor (TCR)-alpha chain in forming preimmune TCR repertoire revealed by clonal TCR reconstitution system. J. Exp. Med. 195: 991-1001.
9. Bouneaud, C., P. Kourilsky, and P. Bousso. 2000. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 13: 829-840.
10. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini, S. L. Topalian, T. Miki, and S. A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91: 3515-3519.
11. Coulie, P. G., V. Brichard, A. Van Pel, T. Wölfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, J. P. Szikora, et al. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180: 35-42.
12. Yee, C., J. A. Thompson, D. Byrd, S. R. Riddell, P. Roche, E. Celis, and P. D. Greenberg. 2002. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99: 16168-16173.
13. Weber, J., W. Boswell, J. Smith, E. Hersh, J. Snively, M. Diaz, S. Miles, X. Liu, M. Obrocea, Z. Qiu, and A. Bot. 2008. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J. Immunother. 31: 215-223.
14. Pittet, M. J., D. E. Speiser, D. Liénard, D. Valmori, P. Guillaume, V. Dutoit, D. Rimoldi, F. Lejeune, J. C. Cerottini, and P. Romero. 2001. Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin. Cancer Res. 7(3 Suppl.): 796s-803s.
15. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
16. Mackensen, A., N. Meidenbauer, S. Vogl, M. Laumer, J. Berger, and R. Andreesen. 2006. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 24: 5060-5069.
17. Khammari, A., N. Labarrière, V. Vignard, J. M. Nguyen, M. C. Pandolfino, A. C. Knol, G. Quéreux, S. Saiagh, A. Brocard, F. Jotereau, and B. Dreno. 2009. Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J. Invest. Dermatol. 129: 2835-2842.
18. Jäger, E., H. Höhn, A. Necker, R. Förster, J. Karbach, K. Freitag, C. Neukirch, C. Castelli, R. D. Salter, A. Knuth, and M. J. Maeurer. 2002. Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1. Int. J. Cancer 98: 376-388.
19. Cormier, J. N., M. L. Salgaller, T. Prevette, K. C. Barracchini, L. Rivoltini, N. P. Restifo, S. A. Rosenberg, and F. M. Marincola. 1997. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. 3: 37-44.
20. Butler, M. O., P. Friedlander, M. I. Milstein, M. M. Mooney, G. Metzler, A. P. Murray, M. Tanaka, A. Berezovskaya, O. Imataki, L. Drury, et al. 2011. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci. Transl. Med. 3: 80ra34.
21. Zippelius, A., M. J. Pittet, P. Batard, N. Rufer, M. de Smedt, P. Guillaume, K. Ellefsen, D. Valmori, D. Liénard, J. Plum, et al. 2002. Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J. Exp. Med. 195: 485-494.
22. Romero, P., D. Valmori, M. J. Pittet, A. Zippelius, D. Rimoldi, F. Lévy, V. Dutoit, M. Ayyoub, V. Rubio-Godoy, O. Michielin, et al. 2002. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol. Rev. 188: 81-96.
23. Trautmann, L., N. Labarrière, F. Jotereau, V. Karanikas, N. Gervois, T. Connerotte, P. Coulie, and M. Bonneville. 2002. Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens. Eur. J. Immunol. 32: 3181-3190.
24. Dietrich, P. Y., F. A. Le Gal, V. Dutoit, M. J. Pittet, L. Trautman, A. Zippelius, I. Cognet, V. Widmer, P. R. Walker, O. Michielin, et al. 2003. Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J. Immunol. 170: 5103-5109.
25. Cole, D. K., F. Yuan, P. J. Rizkallah, J. J. Miles, E. Gostick, D. A. Price, G. F. Gao, B. K. Jakobsen, and A. K. Sewell. 2009. Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. J. Biol. Chem. 284: 27281-27289.
26. Garboczi, D. N., P. Ghosh, U. Utz, Q. R. Fan, W. E. Biddison, and D. C. Wiley. 1996. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384: 134-141.
27. Feng, D., C. J. Bond, L. K. Ely, J. Maynard, and K. C. Garcia. 2007. Structural evidence for a germline-encoded T cell receptor-major histocompatibility complex interaction 'codon'. Nat. Immunol. 8: 975-983.
28. Adams, J. J., S. Narayanan, B. Liu, M. E. Birnbaum, A. C. Kruse, N. A. Bowerman, W. Chen, A. M. Levin, J. M. Connolly, C. Zhu, et al. 2011. T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex. Immunity 35: 681-693.
29. Butler, M. O., and N. Hirano. 2014. Human cell-based artificial antigen-presenting cells for cancer immunotherapy. Immunol. Rev. 257: 191-209.
30. Heemskerk, M. H., M. Hoogeboom, R. A. de Paus, M. G. Kester, M. A. van der Hoorn, E. Goulmy, R. Willemze, and J. H. Falkenburg. 2003. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 102: 3530-3540.
31. Butler, M. O., J. S. Lee, S. Ansén, D. Neuberg, F. S. Hodi, A. P. Murray, L. Drury, A. Berezovskaya, R. C. Mulligan, L. M. Nadler, and N. Hirano. 2007. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin. Cancer Res. 13: 1857-1867.
32. Hirano, N., M. O. Butler, Z. Xia, S. Ansén, M. S. von Bergwelt-Baildon, D. Neuberg, G. J. Freeman, and L. M. Nadler. 2006. Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood 107: 1528-1536.
33. Rimoldi, D., V. Rubio-Godoy, V. Dutoit, D. Lienard, S. Salvi, P. Guillaume, D. Speiser, E. Stockert, G. Spagnoli, C. Servis, et al. 2000. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. J. Immunol. 165: 7253-7261.
34. Chen, Y. T., E. Stockert, A. Jungbluth, S. Tsang, K. A. Coplan, M. J. Scanlan, and L. J. Old. 1996. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc. Natl. Acad. Sci. USA 93: 5915-5919.
35. Yang, S., C. J. Cohen, P. D. Peng, Y. Zhao, L. Cassard, Z. Yu, Z. Zheng, S. Jones, N. P. Restifo, S. A. Rosenberg, and R. A. Morgan. 2008. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther. 15: 1411-1423.
36. Kitamura, T. 1998. New experimental approaches in retrovirus-mediated expression screening. Int. J. Hematol. 67: 351-359.
37. Imataki, O., S. Ansén, M. Tanaka, M. O. Butler, A. Berezovskaya, M. I. Milstein, K. Kuzushima, L. M. Nadler, and N. Hirano. 2012. IL-21 can supplement suboptimal Lck-independent MAPK activation in a STAT-3-dependent manner in human CD8(+) T cells. J. Immunol. 188: 1609-1619.
38. Purbhoo, M. A., J. M. Boulter, D. A. Price, A. L. Vuidepot, C. S. Hourigan, P. R. Dunbar, K. Olson, S. J. Dawson, R. E. Phillips, B. K. Jakobsen, et al. 2001. The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain. J. Biol. Chem. 276: 32786-32792.
39. Okamoto, S., J. Mineno, H. Ikeda, H. Fujiwara, M. Yasukawa, H. Shiku, and I. Kato. 2009. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res. 69: 9003-9011.
40. Ansén, S., M. O. Butler, A. Berezovskaya, A. P. Murray, K. Stevenson, L. M. Nadler, and N. Hirano. 2008. Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21. Clin. Cancer Res. 14: 6125-6136.
41. Hirano, N., M. O. Butler, Z. Xia, A. Berezovskaya, A. P. Murray, S. Ansén, S. Kojima, and L. M. Nadler. 2006. Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia. Blood 108: 2662-2668.
42. Hirano, N., M. O. Butler, Z. Xia, A. Berezovskaya, A. P. Murray, S. Ansén, and L. M. Nadler. 2006. Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses. Clin. Cancer Res. 12: 2967-2975.
43. Tanaka, M., M. O. Butler, S. Ansén, O. Imataki, A. Berezovskaya, L. M. Nadler, and N. Hirano. 2011. Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell. Clin. Cancer Res. 17: 5392-5401.
44. Butler, M. O., S. Ansén, M. Tanaka, O. Imataki, A. Berezovskaya, M. M. Mooney, G. Metzler, M. I. Milstein, L. M. Nadler, and N. Hirano. 2010. A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles. Int. Immunol. 22: 863-873.
45. Butler, M. O., O. Imataki, Y. Yamashita, M. Tanaka, S. Ansén, A. Berezovskaya, G. Metzler, M. I. Milstein, M. M. Mooney, A. P. Murray, et al. 2012. Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell help. PLoS ONE 7: e30229.
46. Li, L. P., J. C. Lampert, X. Chen, C. Leitao, J. Popović, W. Müller, and T. Blankenstein. 2010. Transgenic mice with a diverse human T cell antigen receptor repertoire. Nat. Med. 16: 1029-1034.
47. Carrasco, Y. R., A. R. Ramiro, C. Trigueros, V. G. de Yébenes, M. García-Peydró, and M. L. Toribio. 2001. An endoplasmic reticulum retention function for the cytoplasmic tail of the human pre-T cell receptor (TCR) alpha chain: potential role in the regulation of cell surface pre-TCR expression levels. J. Exp. Med. 193: 1045-1058.
48. Johnson, L. A., B. Heemskerk, D. J. Powell, Jr., C. J. Cohen, R. A. Morgan, M. E. Dudley, P. F. Robbins, and S. A. Rosenberg. 2006. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J. Immunol. 177: 6548-6559.
49. Wieckowski, S., P. Baumgaertner, P. Corthesy, V. Voelter, P. Romero, D. E. Speiser, and N. Rufer. 2009. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J. Immunol. 183: 5397-5406.
50. Valmori, D., V. Dutoit, D. Liénard, F. Lejeune, D. Speiser, D. Rimoldi, V. Cerundolo, P. Y. Dietrich, J. C. Cerottini, and P. Romero. 2000. Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients. J. Immunol. 165: 533-538.
51. Sensi, M., C. Traversari, M. Radrizzani, S. Salvi, C. Maccalli, R. Mortarini, L. Rivoltini, C. Farina, G. Nicolini, T. Wölfel, et al. 1995. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc. Natl. Acad. Sci. USA 92: 5674-5678.
52. Cole, D. K., E. S. Edwards, K. K. Wynn, M. Clement, J. J. Miles, K. Ladell, J. Ekeruche, E. Gostick, K. J. Adams, A. Skowera, et al. 2010. Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J. Immunol. 185: 2600-2610.
53. Dutoit, V., V. Rubio-Godoy, M. J. Pittet, A. Zippelius, P. Y. Dietrich, F. A. Legal, P. Guillaume, P. Romero, J. C. Cerottini, R. A. Houghten, et al. 2002. Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans. J. Exp. Med. 196: 207-216.
54. Chen, J. L., P. R. Dunbar, U. Gileadi, E. Jäger, S. Gnjatic, Y. Nagata, E. Stockert, D. L. Panicali, Y. T. Chen, A. Knuth, et al. 2000. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J. Immunol. 165: 948-955.
55. Boulter, J. M., M. Glick, P. T. Todorov, E. Baston, M. Sami, P. Rizkallah, and B. K. Jakobsen. 2003. Stable, soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng. 16: 707-711.
56. Robbins, P. F., Y. F. Li, M. El-Gamil, Y. Zhao, J. A. Wargo, Z. Zheng, H. Xu, R. A. Morgan, S. A. Feldman, L. A. Johnson, et al. 2008. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 180: 6116-6131.
57. Johnson, L. A., R. A. Morgan, M. E. Dudley, L. Cassard, J. C. Yang, M. S. Hughes, U. S. Kammula, R. E. Royal, R. M. Sherry, J. R. Wunderlich, et al. 2009. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114: 535-546.
58. Li, Y., R. Moysey, P. E. Molloy, A. L. Vuidepot, T. Mahon, E. Baston, S. Dunn, N. Liddy, J. Jacob, B. K. Jakobsen, and J. M. Boulter. 2005. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 23: 349-354.
59. Holler, P. D., P. O. Holman, E. V. Shusta, S. O'Herrin, K. D. Wittrup, and D. M. Kranz. 2000. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc. Natl. Acad. Sci. USA 97: 5387-5392.
60. Weber, K. S., D. L. Donermeyer, P. M. Allen, and D. M. Kranz. 2005. Class II-restricted T cell receptor engineered in vitro for higher affinity retains peptide specificity and function. Proc. Natl. Acad. Sci. USA 102: 19033-19038.
61. Kessels, H. W., M. D. van Den Boom, H. Spits, E. Hooijberg, and T. N. Schumacher. 2000. Changing T cell specificity by retroviral T cell receptor display. Proc. Natl. Acad. Sci. USA 97: 14578-14583.
62. Chervin, A. S., D. H. Aggen, J. M. Raseman, and D. M. Kranz. 2008. Engineering higher affinity T cell receptors using a T cell display system. J. Immunol. Methods 339: 175-184.
63. Schmid, D. A., M. B. Irving, V. Posevitz, M. Hebeisen, A. Posevitz-Fejfar, J. C. Sarria, R. Gomez-Eerland, M. Thome, T. N. Schumacher, P. Romero, et al. 2010. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J. Immunol. 184: 4936-4946.
64. Haidar, J. N., B. Pierce, Y. Yu, W. Tong, M. Li, and Z. Weng. 2009. Structure-based design of a T-cell receptor leads to nearly 100-fold improvement in binding affinity for pepMHC. Proteins 74: 948-960.
65. Zoete, V., M. B. Irving, and O. Michielin. 2010. MM-GBSA binding free energy decomposition and T cell receptor engineering. J. Mol. Recognit. 23: 142-152.
66. Irving, M., V. Zoete, M. Hebeisen, D. Schmid, P. Baumgartner, P. Guillaume, P. Romero, D. Speiser, I. Luescher, N. Rufer, and O. Michielin. 2012. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J. Biol. Chem. 287: 23068-23078.
67. Pierce, B. G., L. M. Hellman, M. Hossain, N. K. Singh, C. W. Vander Kooi, Z. Weng, and B. M. Baker. 2014. Computational design of the affinity and specificity of a therapeutic T cell receptor. PLOS Comput. Biol. 10: e1003478.
68. Dunn, S. M., P. J. Rizkallah, E. Baston, T. Mahon, B. Cameron, R. Moysey, F. Gao, M. Sami, J. Boulter, Y. Li, and B. K. Jakobsen. 2006. Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity. Protein Sci. 15: 710-721.
69. Madura, F., P. J. Rizkallah, K. M. Miles, C. J. Holland, A. M. Bulek, A. Fuller, A. J. Schauenburg, J. J. Miles, N. Liddy, M. Sami, et al. 2013. T-cell receptor specificity maintained by altered thermodynamics. J. Biol. Chem. 288: 18766-18775.
70. Zhao, Y., A. D. Bennett, Z. Zheng, Q. J. Wang, P. F. Robbins, L. Y. Yu, Y. Li, P. E. Molloy, S. M. Dunn, B. K. Jakobsen, et al. 2007. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J. Immunol. 179: 5845-5854.
71. Cameron, B. J., A. B. Gerry, J. Dukes, J. V. Harper, V. Kannan, F. C. Bianchi, F. Grand, J. E. Brewer, M. Gupta, G. Plesa, et al. 2013. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 5: ra103.
72. Linette, G. P., E. A. Stadtmauer, M. V. Maus, A. P. Rapoport, B. L. Levine, L. Emery, L. Litzky, A. Bagg, B. M. Carreno, P. J. Cimino, et al. 2013. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122: 863-871.
73. Morgan, R. A., N. Chinnasamy, D. Abate-Daga, A. Gros, P. F. Robbins, Z. Zheng, M. E. Dudley, S. A. Feldman, J. C. Yang, R. M. Sherry, et al. 2013. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36: 133-151.
74. Wooldridge, L., J. Ekeruche-Makinde, H. A. van den Berg, A. Skowera, J. J. Miles, M. P. Tan, G. Dolton, M. Clement, S. Llewellyn-Lacey, D. A. Price, et al. 2012. A single autoimmune T cell receptor recognizes more than a million different peptides. J. Biol. Chem. 287: 1168-1177.
75. Robins, H. S., S. K. Srivastava, P. V. Campregher, C. J. Turtle, J. Andriesen, S. R. Riddell, C. S. Carlson, and E. H. Warren. 2010. Overlap and effective size of the human CD8+ T cell receptor repertoire. Sci. Transl. Med. 2: 47ra64.
76. Robbins, P. F., R. A. Morgan, S. A. Feldman, J. C. Yang, R. M. Sherry, M. E. Dudley, J. R. Wunderlich, A. V. Nahvi, L. J. Helman, C. L. Mackall, et al. 2011. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29: 917-924.
77. Thomas, S., H. J. Stauss, and E. C. Morris. 2010. Molecular immunology lessons from therapeutic T-cell receptor gene transfer. Immunology 129: 170-177.
78. Bendle, G. M., C. Linnemann, A. I. Hooijkaas, L. Bies, M. A. de Witte, A. Jorritsma, A. D. Kaiser, N. Pouw, R. Debets, E. Kieback, et al. 2010. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 16: 565-570, 1p, 570.
79. van Loenen, M. M., R. de Boer, A. L. Amir, R. S. Hagedoorn, G. L. Volbeda, R. Willemze, J. J. van Rood, J. H. Falkenburg, and M. H. Heemskerk. 2010. Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc. Natl. Acad. Sci. USA 107: 10972-10977.
80. Govers, C., Z. Sebestyén, M. Coccoris, R. A. Willemsen, and R. Debets. 2010. T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. Trends Mol. Med. 16: 77-87.
81. Cohen, C. J., Y. Zhao, Z. Zheng, S. A. Rosenberg, and R. A. Morgan. 2006. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66: 8878-8886.
82. Cohen, C. J., Y. F. Li, M. El-Gamil, P. F. Robbins, S. A. Rosenberg, and R. A. Morgan. 2007. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67: 3898-3903.
83. Kuball, J., M. L. Dossett, M. Wolfl, W. Y. Ho, R. H. Voss, C. Fowler, and P. D. Greenberg. 2007. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109: 2331-2338.
84. Aggen, D. H., A. S. Chervin, T. M. Schmitt, B. Engels, J. D. Stone, S. A. Richman, K. H. Piepenbrink, B. M. Baker, P. D. Greenberg, H. Schreiber, and D. M. Kranz. 2012. Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains. Gene Ther. 19: 365-374.
85. Provasi, E., P. Genovese, A. Lombardo, Z. Magnani, P. Q. Liu, A. Reik, V. Chu, D. E. Paschon, L. Zhang, J. Kuball, et al. 2012. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18: 807-815.